Translational Research in Acute Lung Injury and Pulmonary Fibrosis Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response

Because therapeutic options are lacking for bronchopulmonary dysplasia (BPD), there is an urgent medical need to discover novel targets/drugs to treat this neonatal chronic lung disease. Metformin, a drug commonly used to lower blood glucose in type 2 diabetes patients, may be a novel therapeutic option for BPD by reducing pulmonary inflammation and fibrosis and improving vascularization. We investigated the therapeutic potential of daily treatment with 25 and 100 mg/kg metformin, injected subcutaneously in neonatal Wistar rats with severe experimental BPD, induced by continuous exposure to 100% oxygen for 10 days. Parameters investigated included survival, lung and heart histopathology, pulmonary fibrin and collagen deposition, vascular leakage, right ventricular hypertrophy, and differential mRNA expression in the lungs of key genes involved in BPD pathogenesis, including inflammation, coagulation, and alveolar development. After daily metformin treatment rat pups with experimental BPD had reduced mortality, alveolar septum thickness, lung inflammation, and fibrosis, demonstrated by a reduced influx of macrophages and neutrophils and hyperoxia-induced collagen III and fibrin deposition (25 mg/kg), as well as improved vascularization (100 mg/kg) compared with control treatment. However, metformin did not ameliorate alveolar enlargement, small arteriole wall thickening, vascular alveolar leakage, and right ventricular hypertrophy. In conclusion metformin prolongs survival and attenuates pulmonary injury by reducing pulmonary inflammation, coagulation, and fibrosis but does not affect alveolar development or prevent pulmonary arterial hypertension and right ventricular hypertrophy in neonatal rats with severe hyperoxia-induced experimental BPD.

[1]  K. Komori,et al.  Metformin stimulates ischemia-induced revascularization through an eNOS dependent pathway in the ischemic hindlimb mice model. , 2015, Journal of vascular surgery.

[2]  S. Safe,et al.  Mechanism of Metformin-dependent Inhibition of Mammalian Target of Rapamycin (mTOR) and Ras Activity in Pancreatic Cancer , 2014, The Journal of Biological Chemistry.

[3]  L. McCullough,et al.  Chronic metformin treatment improves post‐stroke angiogenesis and recovery after experimental stroke , 2014, The European journal of neuroscience.

[4]  Yuan-yuan Wu,et al.  Activation of AMPK inhibits pulmonary arterial smooth muscle cells proliferation , 2014, Experimental lung research.

[5]  E. Antunes,et al.  Metformin Attenuates the Exacerbation of the Allergic Eosinophilic Inflammation in High Fat-Diet-Induced Obesity in Mice , 2013, PloS one.

[6]  F. Walther,et al.  Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[7]  E. Rozengurt,et al.  Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. , 2013, Biochemical and biophysical research communications.

[8]  Chan Sun Park,et al.  Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. , 2012, Biochemical pharmacology.

[9]  H. Choi,et al.  Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. , 2012, Biochemical and biophysical research communications.

[10]  E. Goncharova,et al.  mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Jae Heun Lee,et al.  Metformin inhibits HMGB1 release in LPS‐treated RAW 264.7 cells and increases survival rate of endotoxaemic mice , 2011, British journal of pharmacology.

[12]  A. Salminen,et al.  AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan , 2011, Journal of Molecular Medicine.

[13]  F. Walther,et al.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats. , 2010, American journal of respiratory and critical care medicine.

[14]  H. Komura,et al.  Metformin, an Antidiabetic Agent, Suppresses the Production of Tumor Necrosis Factor and Tissue Factor by Inhibiting Early Growth Response Factor-1 Expression in Human Monocytes in Vitro , 2010, Journal of Pharmacology and Experimental Therapeutics.

[15]  T. Mariani,et al.  PPARγ deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution , 2010, Respiratory research.

[16]  C. Bernstein,et al.  Novel Anti-Inflammatory Action of 5-Aminoimidazole-4-carboxamide Ribonucleoside with Protective Effect in Dextran Sulfate Sodium-Induced Acute and Chronic Colitis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[17]  Simon C Watkins,et al.  AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. , 2010, American journal of respiratory cell and molecular biology.

[18]  Zhenggang Yang,et al.  Macrophage α1 AMP-activated Protein Kinase (α1AMPK) Antagonizes Fatty Acid-induced Inflammation through SIRT1* , 2010, The Journal of Biological Chemistry.

[19]  R. Steinhorn.  Neonatal pulmonary hypertension , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[20]  P. Pacaud,et al.  Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension , 2009, British journal of pharmacology.

[21]  J. Bastarache,et al.  Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[22]  Shailendra Giri,et al.  Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis1 , 2009, The Journal of Immunology.

[23]  F. Walther,et al.  Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury , 2009, Respiratory research.

[24]  J. B. Kim,et al.  Berberine suppresses proinflammatory responses through AMPK activation in macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[25]  S. Abman.  Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. , 2009, Annual review of medicine.

[26]  E. Baraldi,et al.  Chronic lung disease after premature birth. , 2007, The New England journal of medicine.

[27]  F. Walther,et al.  Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[28]  Kunihiro Suzuki,et al.  Metformin Inhibits Cytokine-Induced Nuclear Factor &kgr;B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells , 2006, Hypertension.

[29]  James L. Young,et al.  Metformin Inhibits Proinflammatory Responses and Nuclear Factor-&kgr;B in Human Vascular Wall Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[31]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[32]  S. Abman,et al.  171 RECOMBINANT HUMAN VEGF TREATMENT ENHANCES ALVEOLARIZATION AFTER HYPEROXIC LUNG INJURY IN NEONATAL RATS , 2005, Journal of Investigative Medicine.

[33]  A. Tanswell,et al.  Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. , 2004, American journal of respiratory and critical care medicine.

[34]  T. van der Poll,et al.  Bidirectional Relation Between Inflammation and Coagulation , 2004, Circulation.

[35]  I. Kang,et al.  5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. , 2004, Biochemical and biophysical research communications.

[36]  F. Walther,et al.  Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. , 2004, Free radical biology & medicine.

[37]  N. Wiernsperger,et al.  Microcirculation in insulin resistance and diabetes: more than just a complication. , 2003, Diabetes & metabolism.

[38]  A. Jobe.  The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.

[39]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[40]  A. Tanswell,et al.  α1-Antitrypsin Protects Neonatal Rats from Pulmonary Vascular and Parenchymal Effects of Oxygen Toxicity , 1994, Pediatric Research.

[41]  J. Amiral,et al.  Evolution of Antibodies Anti-PF4/heparin in a Patient with a History of Heparin-induced Thrombocytopenia Reexposed to Heparin , 1994, Thrombosis and Haemostasis.

[42]  U. Smith,et al.  Effects of Metformin and Metoprolol CR on Hormones and Fibrinolytic Variables during a Hyperinsulinemic, Euglycemic Clamp in Man , 1994, Thrombosis and Haemostasis.

[43]  R. Seitz,et al.  Protein C degradation in vitro by neutrophil elastase. , 1991, Biological chemistry Hoppe-Seyler.

[44]  T. Martin,et al.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. , 1989, The Journal of clinical investigation.

[45]  E. Bosisio,et al.  Metformin Improves Peripheral Vascular Flow in Nonhyperlipidemic Patients with Arterial Disease , 1984, Journal of cardiovascular pharmacology.

[46]  R. Teng,et al.  AMP kinase activation improves angiogenesis in pulmonary artery endothelial cells with in utero pulmonary hypertension. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[47]  F. Walther,et al.  Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. , 2012, American journal of physiology. Lung cellular and molecular physiology.